U.S. FTC approves Baxter's acquisition of Claris business with condition

Telogica

20/07/2017 19:59

WASHINGTON, July 20 (Reuters) - Baxter International Inc 
 BAX.N  and Claris Lifesciences Ltd  CLAI.BO  have agreed to 
divest two types of pharmaceutical products to settle U.S. 
Federal Trade Commission charges that Baxter's proposed 
acquisition of Claris' injectable drugs business is 
anticompetitive, the agency said on Thursday. 
    The $625 million acquisition was announced by Baxter in 
December and the company said it expected the deal to close in 
the second half of 2017. 
 
 (Reporting by Eric Beech; Writing by Washington Newsroom; 
Editing by Eric Walsh) 
 ((+1 202 898 8322)) 
 
Keywords: CLARIS LIFE M&A/BAXTER INTL